Paradigm Shift Therapeutics, LLC (PSTx) is an immuno-oncology company founded to radically transform current cancer therapy into cures by using cutting edge immunotherapy research and partnering with collaborators to utilize state of the art drug discovery and development resources. We are focused on developing inhibitors of CD47, a novel and powerful immuno-oncology target for a variety of cancers.

PSTx is grateful for ongoing funding from the Avon Foundation for Women and for the business development support from BioHealth Innovation.